P. Bardy
Royal Melbourne Hospital
7 Papers
115 Citations
P. Bardy is an academic researcher from Royal Melbourne Hospital. The author has contributed to research in topics: Transplantation & Granulocyte colony-stimulating factor. The author has an hindex of 4, co-authored 7 publications.
Chat about Author
Papers
Fludarabine-based non-myeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukaemia and lymphoma.
TL;DR: Preliminary observations suggest fludarabine-based non-myeloablative chemotherapy followed by reinfusion of G-CSF-mobilised allogeneic peripheral blood progenitor cells results in engraftment and GVHD/graft-versus-tumour effects similar to myeloablatives and may provide an alternative in patients ineligible for conventional conditioning regimens.
75
Early cyclosporine taper in high-risk sibling allogeneic bone marrow transplants
TL;DR: Non- randomised experience indicates that a rapid taper of CYA is tolerable and may provide an alternative to immunotherapy with donor leukocyte infusion in the high-risk allograft setting.
35
G-CSF stimulated donor granulocyte collections for prophylaxis and therapy of neutropenic sepsis.
TL;DR: G-CSF mobilised granulocyte collections are feasible and the preliminary evidence suggests that the infusion of these cells may be useful early in the prophylaxis or treatment of severe neutropenic sepsis.
33
The addition of allogeneic peripheral blood-derived progenitor cells to bone marrow for transplantation: results of a randomised clinical trial.
TL;DR: Allogeneic PBPC from HLA-identical siblings may speed engraftment of neutrophils and platelets without detrimental effects on GVHD or survival.
7
Factors influencing the outcome of donor marrow transplantation in adults from less than ideal donors: experience from two Australian centres.
TL;DR: The results of 78 marrow transplants in two Australian hospitals between 1991 and 1996 suggest that an extended family or unrelated donor transplant should generally be limited to patients with a good performance status and early phase but otherwise incurable haematological disease.
4